1 Top Canadian Pot Stock to Buy on Sale

Organigram Holdings (TSX:OGI)(NASDAQ:OGI) is a top pot stock that is trading at a discount. Shares have lost a third of their value over one month.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Organigram Holdings (TSX:OGI)(NASDAQ:OGI) is a top Canadian pot stock that is currently trading at a discount. The company reported lower revenue in the second quarter, but sales are expected to improve in the third quarter.

Organigram missed estimates in Q2 2021

Organigram posted second-quarter revenue below analyst expectations. The pot company’s net revenue was $14.6 million in the second quarter of 2021 compared to $23.2 million in the same quarter a year earlier. Organigram missed analysts’ estimates of $19.1 million. Q2 2021 net revenue decreased compared to Q2 2020 mainly due to a significant drop in wholesale revenue and a lower average selling price in Q2 2021.

Net sales were also lower due to missed sales opportunities, with some employees testing positive for COVID-19, forcing a significant number of facility staff to isolate.

The Canadian cannabis company recorded a net loss of $66.4 million in the quarter ended February 28, significantly larger than the loss of $6.8 million in Q2 2020. Organigram currently has $232 million in cash and short-term investments.

Organigram’s CEO Greg Engel said, “Although second quarter 2021 results have been called into question by industry dynamics, COVID-19 and staff limitations at our plant, we believe it there are excellent prospects for the industry, Organigram and our shareholders … In the shorter term, we are currently looking to generate higher revenues in the third quarter of 2021 as our new product portfolio continues to gain traction and we become better equipped to meet demand.”

Organigram expects Q3 2021 revenue to be higher than Q2 2021, as the company improves demand fulfillment with increased staffing.

Organigram signed a deal with British American Tobacco

In March, Organigram signed an agreement with a subsidiary of British American Tobacco (BAT), under which the British company will take a 19.9% stake in the cannabis producer for $221 million. Under the agreement, BAT will purchase 58.3 million Organigram shares at a price of $3.792 each.

Organigram says it has also signed a product development collaboration agreement with BAT, which will see the creation of a “centre of excellence” that will focus on the development of the next generation of cannabis products with an initial focus on CBD.

According to Organigram, BAT’s investment is expected to accelerate its research and development program and product development activities in addition to strengthening its ability to penetrate U.S. and international markets.

Last week, the cannabis company acquired The Edibles & Infusions Corp. This acquisition positions Organigram to drive significant incremental near-term revenue growth from soft chews, the largest edible product category.

Raymond James analyst Rahul Sarugaser said the deal will help consolidate Organigram’s already strong position in the Canadian edibles market and add quality soft paste manufacturing expertise to its range of chocolate products.

The company is targeting first sales of chews in the fourth quarter of 2021 subject to certain achievements, including, but not limited to, the timing of receipt and commissioning of certain ancillary equipment, completion of documentation of quality assurance, hiring of required staff, and obtaining product listings from provincial boards.

The pot stock is undervalued

Organigram stock has a five-year PEG ratio of 0.11. A PEG ratio under one indicates that a company is undervalued based on its future expected growth. As its PEG is near zero, Organigram is very cheap. The pot stock has lost a third of its value over one month.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends OrganiGram Holdings. 

More on Cannabis Stocks

Retirement plan
Dividend Stocks

4 Stocks That Could Turn $100,000 Into $500,000 by the Time You Retire

Companies such as Brookfield Asset Management have the potential to consistently beat the broader markets and deliver stellar returns to…

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Cannabis Stocks

TFSA Investors: 2 U.S. Stocks I’m Never Selling

Canadians looking to diversify their portfolios and gain exposure to U.S. stocks can purchase shares of high-growth companies such as…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Canopy Growth Stock Climbed as Much as 20% on Monday

A glimmer of hope from the U.S. Congress may lead to renewed interest in marijuana investing.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Friday, July 15

A continued selloff in metals prices is likely to pressure the commodity-heavy TSX Composite benchmark at the open today.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy!

After selling off for years, Organigram stock now offers tonnes of value and is easily one of the best cannabis…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »